Mission Therapeutics Limited

Cambridge Enterprise Limited

Xavier Jacq

Stephen Philip Jackson

Helen Robinson

Paul Wijnhoven

Ryotaro Nishi

Quentin Gueranger

Yaara Ofir-Rosenfeld

Jeanine Ann Harrigan

The present application relates to materials and methods for exploiting synthetic lethality and/or chemo-sensitisation in DNA damage response (DDR) pathways. In particular, the application relates to ubiquitin hydrolase protein Ubiquitin Specific Protease 4 (USP4) and its association with DDR pathways. Further, the use of USP4 inhibitors in the treatment of cancer and methods of screening is described, in particular, use of inhibitors of USP4 in the treatment of tumours defective in double-strand break repair (DSBR) and/or tumours resistant to platinum-based chemotherapy, or to sensitise, i.e. chemosensitise or radiosensitise tumours to other therapeutic agents.

Methods of screening and treatment with USP4 inhibitors

The present invention relates to materials and methods for high throughput monitoring of target engagement of isopeptidases, such as deubiquitylating enzymes by, inter alia, small molecule inhibitors. In particular the invention relates to development of high throughput assays to measure isopeptidase activity in biological samples, such as cells, animal tissues, animal tumours, human tissue or patient-derived biopsies.

Methodologies for measuring isopeptidase activity in biological samples in a high throughput manner

Growing community of inventors

Cambridge, United Kingdom

Xavier Jacq